FDAs new approval: yeztugo (lenacapavir): a longer lasting avenue against HIV
Journal of the Pakistan Medical AssociationDear Editor, The human immunodeficiency virus is an RNA retrovirus transmitted through bodily fluids: blood, semen, pre-seminal fluid, rectal fluids, vaginal fluids, and breast milk.
Maryam Tanveer, Ahsan Kamal
doaj +2 more sources
Lenacapavir-induced lattice hyperstabilization is central to HIV-1 capsid failure at the nuclear pore complex and in the cytoplasm [PDF]
eLifeLenacapavir (LEN) is the first human immunodeficiency virus type 1 (HIV-1) capsid inhibitor approved for clinical use in humans. It inhibits multiple steps of the viral life cycle; however, the molecular details of the effect of LEN on capsid structure ...
Arpa Hudait +4 more
doaj +2 more sources
Practical Synthesis of 7-Bromo-4-chloro-1H-indazol-3-amine: An Important Intermediate to Lenacapavir
Molecules7-Bromo-4-chloro-1H-indazol-3-amine is a heterocyclic fragment used in the synthesis of Lenacapavir, a potent capsid inhibitor for the treatment of HIV-1 infections.
Naeem Asad +9 more
doaj +2 more sources
Lenacapavir initiation with concomitant primidone: A case report with therapeutic drug monitoring. [PDF]
Br J Clin PharmacolLenacapavir (LEN), a first‐in‐class capsid inhibitor, has unique pharmacokinetics that enable twice‐yearly dosing. LEN is not extensively metabolized, although it is a substrate of CYP3A4, which introduces drug–drug interactions concerns. As adoption and implementation of LEN for treatment and prevention increase, additional guidance on concomitant ...
Devanathan AS +6 more
europepmc +2 more sources
Pharmacologic hyperstabilisation of the HIV-1 capsid lattice induces capsid failure
eLifeThe HIV-1 capsid has emerged as a tractable target for antiretroviral therapy. Lenacapavir, developed by Gilead Sciences, is the first capsid-targeting drug approved for medical use.
KM Rifat Faysal +12 more
doaj +2 more sources
Potential impact and cost-effectiveness of long-acting injectable lenacapavir plus cabotegravir as HIV treatment in Africa [PDF]
Nature CommunicationsAlthough viral suppression is attained for most adults living with diagnosed HIV in East, Central, Southern and West Africa (ECSWA), challenges remain with sustained adherence to daily oral pill taking for some in the population.
Andrew Phillips +15 more
doaj +2 more sources
A Concise Process to Lenacapavir Sodium: Demonstration of One-Pot Sequential Heck/Suzuki-Miyaura Couplings in Lenacapavir API Synthesis. [PDF]
Org Process Res DevThis article presents a new three-step process for lenacapavir sodium, a first-in-class HIV capsid inhibitor developed by Gilead Sciences. Lenacapavir has received FDA approval for both the treatment of multidrug-resistant HIV (SunlencaⓇ, 2022) and PrEP (YeztugoⓇ, 2025).
Guthrie D +13 more
europepmc +4 more sources
Global regulatory collaboration for the assessment of lenacapavir as a long-acting pre-exposure prophylaxis against HIV infection [PDF]
Frontiers in Public HealthHendy Kristyanto +6 more
doaj +2 more sources
PROCESS FOR THE PREPARATION OF AMORPHOUS LENACAPAVIR SODIUM [PDF]
The present disclosure relates to preparation of amorphous Lenacapavir sodium by spray drying ...
Anonymous,
core +4 more sources
Lenacapavir and global HIV prevention: a breakthrough at risk of leaving millions behind. [PDF]
Ann Med Surg (Lond)In June 2025, the FDA approved Lenacapavir, a twice-yearly injectable for HIV pre-exposure prophylaxis (PrEP), following striking trial results showing near-perfect efficacy. This long-acting injectable represents a game-changing innovation, promising to
Miteu GD.
europepmc +2 more sources